Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer

American Surgeon

Volumn 80, Issue 2, 2014, Pages 171-177

  Koslow, Starr B ^b   Eisenberg, Rachel E K ^a   Qiu, Queenie ^a   Chen, Zhengming ^c   Swistel, Alexander ^b   Shin, Sandra J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Departments of Breast Surgery   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; DOXORUBICIN; LETROZOLE; PACLITAXEL; TIPIFARNIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; ADJUVANT THERAPY; AXILLA; BREAST TUMOR; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; FOLLOW UP; IMMUNOHISTOCHEMISTRY; LYMPH NODE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; RISK; RISK ASSESSMENT; SEGMENTAL MASTECTOMY; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BIOPSY, NEEDLE; BREAST NEOPLASMS; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897573483     PISSN: 00031348     EISSN: 15559823     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie. Lancet 1992;339:1245-8.
2. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillarylymph- node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8:881-8.
3. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609.
4. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004;240:462-8; discussion 468-71.
5. Noguchi M. Current controversies concerning sentinel lymph node biopsy for breast cancer. Breast Cancer Res Treat 2004;84: 261-71.
6. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-75.
7. Akay CL, Meric-Bernstam F, Hunt KK, et al. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 2012;19:901-7.
8. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
9. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26: 778-85.
10. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.
11. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-702.
12. Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol 2009;16:551-63.
13. Tan VK, Goh BK, Fook-Chong S, et al. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer-A systematic review and meta-Analysis. J Surg Oncol 2011;104: 97-103.
14. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual (7th ed). New York, NY: Springer; 2010.
15. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000;18:3480-6.
16. Kuerer HM, Singletary SE, Buzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 2001;182: 601-8.
17. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
18. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-6.
19. Brown AS, Hunt KK, Shen J, et al. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 2010; 116:2878-83.
20. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-A multicenter validation study. N Engl J Med 1998; 339:941-6.
21. Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001;233:51-9.